Silo Pharma Secures US Patent For Post-Traumatic Stress Disorder

Silo Pharma, Inc. is a biopharmaceutical company fascinated with innovating in drug delivery and psychedelic therapeutics and advancing novel drug formulations. Today, the company has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application, 17/954,864. The patent is titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,” which strengthens intellectual property protections around the company’s lead candidate, SPC-15, an intranasal treatment designed to address post-traumatic stress disorder (PTSD).

“We are pleased to start 2025 with this expected addition to our intellectual property portfolio. The approval of this patent broadens protection for SPC-15 and expands our technology rights,” commented Eric Weisblum, CEO of Silo.

Following the Notice of Allowance, Silo submitted the necessary paperwork and fees, and the company expects formal patent issuance within 90 days. This new patent builds on Silo’s existing intellectual property, including U.S. Patent 11,491,120, granted in February 2023. Silo has an exclusive licensing agreement with Columbia University to develop, manufacture, and commercialise SPC-15 on a global scale. The agreement also provides Silo access to strengthen its portfolio of issued patents and pending applications related to SPC-15 technology.